This trial evaluates the combination of an anti-PD-L1 antibody (avelumab) with a CDK4/6 kinase inhibitor (palbociclib) in patients with HR+/HER2− advanced BC and TNBC. This evidence concerns the gene ERBB2 and breast cancer.